Thrivent Small Cap Stock Fund Q1 2026 Performance Commentary
Thrivent Asset Management released its first-quarter 2026 commentary for the Thrivent Small Cap Stock Fund, revealing that the fund underperformed the Russell 2000 Index over both the last quarter and the past year. The primary driver of this underperformance was attributed to security selection decisions. Specifically, a significant number of holdings sensitive to artificial intelligence risks experienced value declines amid growing market concerns, prompting portfolio managers to reduce exposure to these positions after thorough evaluation. Additionally, the fund’s underweight positioning in the Pharmaceuticals and Biotechnology sub-industries significantly detracted from returns, as both sectors delivered strong performance during the period. In response to shifting market dynamics and evolving investment theses, the management team actively adjusted the portfolio by initiating or adding positions in multiple sectors while reducing or selling others where thesis validity had diminished. This report highlights the challenges faced by active managers in navigating sector-specific volatility and thematic risks, particularly within the small-cap landscape. The commentary serves as an update for investors regarding strategic adjustments and performance attribution for the specified period.
Wire timeline
Thrivent Small Cap Stock Fund Q1 2026 Performance Commentary
Thrivent Asset Management released its first-quarter 2026 commentary for the Thrivent Small Cap Stock Fund, revealing that the fund underperformed the Russell 2000 Index over both the last quarter and the past year. The primary driver of this underperformance was attributed to security selection decisions. Specifically, a significant number of holdings sensitive to artificial intelligence risks experienced value declines amid growing market concerns, prompting portfolio managers to reduce exposure to these positions after thorough evaluation. Additionally, the fund’s underweight positioning in the Pharmaceuticals and Biotechnology sub-industries significantly detracted from returns, as both sectors delivered strong performance during the period. In response to shifting market dynamics and evolving investment theses, the management team actively adjusted the portfolio by initiating or adding positions in multiple sectors while reducing or selling others where thesis validity had diminished. This report highlights the challenges faced by active managers in navigating sector-specific volatility and thematic risks, particularly within the small-cap landscape. The commentary serves as an update for investors regarding strategic adjustments and performance attribution for the specified period.
All Articles on Seeking Alpha